29 results on '"Vuagnat A"'
Search Results
2. Absence of significant clinical benefit for a systematic routine creatine phosphokinase measurement in asymptomatic patients treated with anti-programmed death protein (ligand) 1 immune checkpoint inhibitor to screen cardiac or neuromuscular immune-related toxicities
3. Chemotherapy beyond immune checkpoint inhibitors in patients with metastatic colorectal cancer
4. Impact of aging on immune-related adverse events generated by anti–programmed death (ligand)PD-(L)1 therapies
5. How does the application of surgical components in enhanced recovery programs for colorectal surgery change over time?
6. Antibiotic therapy duration for prosthetic joint infections treated by Debridement and Implant Retention (DAIR): Similar long-term remission for 6 weeks as compared to 12 weeks
7. Two consecutive deep sinus tract cultures predict the pathogen of osteomyelitis
8. 2158P A self-assessment survey to identify the risk of patient’s screen fail in phase I clinical trials (SCITEP trial)
9. SIOG2022-0154 - Use of the Geriatric Core Dataset for older patients included in early phase trials
10. SIOG2022-0098 - High prevalence of Clonal Hematopoiesis of indeterminate potential (CHIP) associated mutations in elderly patients with solid tumors
11. 1405P Circulating tumor DNA in advanced prostate cancer: Focus on high blood tumor mutational burden (h-bTMB)
12. 472P Prognostic markers in patients (pts) with solid tumors submitted to bispecific T-cell engagers in phase I (phI) clinical trials
13. 1801MO Neutrophils are associated with resistance to anti-PD-1 monotherapy in mismatch repair-deficient tumors
14. Multiple immune-related toxicities in cancer patients treated with anti-programmed cell death protein 1 immunotherapies: a new surrogate marker for clinical trials?
15. 113P Efficacy of oral etoposide associated with trastuzumab in HER2-positive metastatic breast cancer: Results from the Institut Curie’s database
16. Activation of the alternative pathway of human complement by autologous cells expressing transmembrane recombinant properdin
17. 2P Lung immune prognostic index (LIPI) can identify the fast-progressor to immune checkpoints inhibitors (ICI) in microsatellite instability (MSI) or mismatch repair deficient (dMMR) tumours
18. 1047P Long terms efficacy of anti-PD(L)1 in MSI tumours
19. 54P - Applicability of the LIPI score to metastatic microsatellite instability high cancer patients treated with immune checkpoint inhibitors
20. 49P - Thromboembolic risk assessment in patients receiving combination of anti-angiogenic plus anti-PD1 or anti-PD-L1: A descriptive study
21. P136 - SAFETY PROFILE OF COMBINATION THERAPY WITH IMMUNE CHECKPOINT BLOCKERS AND VEGF INHIBITORS IN OLDER PATIENTS TREATED IN EARLY PHASE CLINICAL TRIALS
22. 1294P - Clinical significance of immune-related creatine phosphokinase increase associated with anti PD1/PD-L1 immunotherapies
23. 1025P - Baseline IPI (immune prognostic index) predicts survival in patients with advanced cervical cancer treated with immune checkpoint inhibitors (ICI)
24. 500P - Are epigenetic therapies modifying sensitivity to conventional chemotherapy?
25. 397PD - Precision medicine for patients with primary brain tumours: Molecular screening for cancer treatment optimization (MOSCATO) prospective trial
26. 1843P - Molecular alterations and matched treatment in older patients: Results from the MOSCATO 01 trial
27. FITTING ASYMPTOTIC REGRESSION CURVES WITH DIFFERENT ASYMPTOTES
28. North American Ophiolites: edited by R. G. Coleman and W. P. Irwin. Bull. 95 Department of Geology and Mineral Deposits, State of Oregon. 1977. 183 pp. U.S. $7.00
29. Igneous Rocks of the British Isles: Edited by D. S. Sutherland. Wiley, 1982, 645 p., £55
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.